Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Adagio Medical Holdings (ADGM) Research & Development (2023 - 2026)

Adagio Medical Holdings has reported Research & Development over the past 4 years, most recently at $2.7 million for Q1 2026.

  • Quarterly Research & Development fell 25.09% to $2.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Mar 2026, down 13.28% year-over-year, with the annual reading at $10.6 million for FY2025, 129.59% up from the prior year.
  • Research & Development was $2.7 million for Q1 2026 at Adagio Medical Holdings, up from $2.2 million in the prior quarter.
  • Over five years, Research & Development peaked at $4.4 million in Q3 2023 and troughed at $1.2 million in Q3 2024.
  • The 4-year median for Research & Development is $2.8 million (2025), against an average of $2.7 million.
  • Year-over-year, Research & Development crashed 72.45% in 2024 and then soared 127.94% in 2025.
  • A 4-year view of Research & Development shows it stood at $1.8 million in 2023, then plummeted by 31.4% to $1.2 million in 2024, then soared by 83.65% to $2.2 million in 2025, then grew by 22.64% to $2.7 million in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Research & Development are $2.7 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025).